Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated VRTX.

RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from $407 to $408.

Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF IYF as her final trade.

Don’t forget to check out our premarket coverage here

Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. NFLX, saying the stock is close to its 52-week high.

Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix from Neutral to Buy and raised the price target from $850 to $1100.

Price Action:

• Vertex Pharmaceuticals shares gained 0.5% to close at $502.55 on Thursday.
• iShares U.S. Financials ETF fell 0.6% during Thursday’s session.
• Netflix shares gained 0.6% to close at $976.72 on Thursday.

Check This Out:

Photo: Shutterstock